[A21-99] Nivolumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2021
Commission awarded on 27.07.2021 by the Federal Joint Committee (G-BA).
Adults with metastatic colorectal cancer with mismatch repair deficiency (dMMR) or high microsatellite instability after prior fluoropyrimidine-based combination chemotherapy
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.